Table 2.
Basal characteristics of RA patients in the included studies [18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34].
| Age (Years) | Women | RA Duration | RF+ | ACPA+ | RA Activity | Structural Damage | |
|---|---|---|---|---|---|---|---|
| IFX | 45–55 | 60–71% | 5–7.4 months | 61–67% | Hasta 90% | DAS28 > 5 | 70% |
| ADA | 46–56 | 63–79% | 3–4.4 months | 69–74% | - | DAS28 5.5–6.3 | SHS 6.3–7.5 |
| ETN | 48 | 76% | 7 months | 53% | 77% | DAS28-CRP 4.17 | mTTS 6.69–8.01 |
| CZP | 50–52 | 69–76% | 3–7 months | 72–97% | - | DAS28 6.7 | 77.3% |
| TCZ | 53–55 | 61–76% | 1 month | 75% | - | DAS28 5.2 | SHS 0 |
Abbreviations: RA = rheumatoid arthritis; RF = rheumatoid factor; ACPA = anti-citrullinated peptide antibodies; IFX = infliximab; ADA = adalimumab; ETN = etanercept; CZP = certolizumab pegol; TCZ = tocilizumab; DAS28 = disease activity score of 28 joints; CRP = C reactive protein; SHS = Sharp-van der Heijde index; mTTS = modified Sharp-van der Heijde index.